ストックスクリーナーアプリを入手
5.59
4.10%
0.22
前日終値:
$5.37
開ける：
$5.4
24時間の取引高:
12,037
Relative Volume:
0.30
時価総額：
$31.22M
収益：
$147.75M
当期純損益:
$-284.23M
株価収益率:
-1.9078
EPS:
-2.93
ネットキャッシュフロー:
$-317.54M
1週間 パフォーマンス:
+6.07%
1か月 パフォーマンス:
-28.63%
6か月 パフォーマンス:
-65.64%
1年 パフォーマンス:
-72.37%
1日の値動き範囲:
$5.40
$5.6265
1週間の範囲:
$5.20
$5.7287
52週間の値動き範囲:
$4.50
$38.25
Fibrogen Inc Stock (FGEN) Company Profile
FGEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
5.6265 | 31.22M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.21 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.65 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.40 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.55 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.95 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-26 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | ダウングレード | Stifel | Buy → Hold |
| 2023-06-26 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | アップグレード | Stifel | Hold → Buy |
| 2023-01-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-09-22 | ダウングレード | Goldman | Neutral → Sell |
| 2021-08-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-07-16 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-03-31 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-03-02 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-26 | 開始されました | Raymond James | Underperform |
| 2020-07-10 | 再開されました | Stifel | Buy |
| 2020-05-01 | 開始されました | Cowen | Market Perform |
| 2020-04-27 | 開始されました | BofA/Merrill | Neutral |
| 2019-05-29 | 再開されました | Goldman | Neutral |
| 2019-05-10 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | 開始されました | Piper Jaffray | Neutral |
| 2019-02-11 | 再開されました | Stifel | Buy |
| 2018-12-19 | アップグレード | Citigroup | Neutral → Buy |
| 2017-08-08 | 繰り返されました | Leerink Partners | Outperform |
| 2017-08-08 | 繰り返されました | Stifel | Buy |
| 2017-07-21 | ダウングレード | Goldman | Buy → Neutral |
| 2017-07-11 | 開始されました | Jefferies | Buy |
| 2016-02-11 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | 開始されました | Credit Suisse | Neutral |
| 2015-12-04 | 開始されました | Citigroup | Buy |
| 2015-09-23 | 開始されました | Lake Street | Hold |
| 2015-07-29 | 開始されました | Citigroup | Buy |
| 2015-07-20 | アップグレード | Goldman | Neutral → Buy |
| 2014-12-09 | 開始されました | Stifel | Buy |
すべてを表示
Fibrogen Inc (FGEN) 最新ニュース
FibroGen (FGEN) Trading Halted Pending News Release | FGEN Stock News - GuruFocus
FibroGen Enters New Agreement with HiFiBiO - TipRanks
Fibrogen IncOn June 12 Enters Termination, Asset Transfer And License Agreement With Hifibio - MarketScreener
FibroGen (FGEN) Announces 1-for-25 Reverse Stock Split | FGEN St - GuruFocus
FibroGen to implement 1-for-25 reverse stock split; shares down 15% - MSN
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Adobe, RH And 3 Stocks To Watch Heading Into FridayAdobe (NASDAQ:ADBE), FibroGen (NASDAQ:FGEN) - Benzinga
FibroGen Announces 1-for-25 Reverse Stock Split | FGEN Stock New - GuruFocus
FibroGen Announces Reverse Stock Split Effective June 16 - TipRanks
FibroGen to Implement 1-for-25 Reverse Stock Split - marketscreener.com
FibroGen To Implement 1-for-25 Reverse Stock Split - Nasdaq
FibroGen, Inc. Announces 1-for-25 Reverse Stock Split Effective June 16, 2025 - Nasdaq
Fibrogen Announces 1-For-25 Reverse Stock Split - marketscreener.com
FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewswire
FibroGen's Massive 1-for-25 Reverse Split Cuts 101M Shares to 4MWhat Investors Must Know - Stock Titan
Millennium Management LLC Lowers Stock Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen expands board with biotech veteran Kauffman By Investing.com - Investing.com South Africa
FibroGen expands board with biotech veteran Kauffman - Investing.com Australia
FibroGen Amends Financing Agreement for Flexibility - TipRanks
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors | FGEN Stock News - GuruFocus
Fibrogen Appoints Michael Kauffman To Its Board Of Directors - marketscreener.com
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - GlobeNewswire
FibroGen Strengthens Board with Velcade Developer: Key Move for Pipeline Advancement - Stock Titan
Squarepoint Ops LLC Takes Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Two Sigma Advisers LP Has $465,000 Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen, Inc. (NASDAQ:FGEN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com - Defense World
FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline - MSN
FibroGen Q1 2025 slides: China sale to extend cash runway amid revenue decline By Investing.com - Investing.com South Africa
FibroGen First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
FibroGen Q1 2025 slides: China sale to extend cash runway amid revenue decline - Investing.com Australia
HC Wainwright Has Negative Outlook for FibroGen Q2 Earnings - Defense World
FibroGen’s Earnings Call: Strategic Gains Amid Revenue Woes - TipRanks
FibroGen (NASDAQ:FGEN) Earns Buy Rating from HC Wainwright - Defense World
FibroGen (FGEN) Boosts Sale Proceeds from Chinese Division - GuruFocus
FibroGen (FGEN) Receives Reaffirmed Buy Rating from HC Wainwrigh - GuruFocus
FibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
FibroGen Inc earnings beat by $0.15, revenue fell short of estimates - Investing.com UK
FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid ... - Yahoo Finance
FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid Revenue Decline - GuruFocus
FibroGen Reports Q1 2025 Earnings and Strategic Updates - TipRanks
Earnings call transcript: FibroGen Q1 2025 sees revenue drop, stock rises - Investing.com Canada
FibroGen Q1 2025 Earnings Call Transcript - MarketBeat
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
FibroGen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
FibroGen Inc Reports Q1 2025 Earnings: Revenue Surpasses Estimates at $2.7M, EPS Misses with $0.16 Loss - GuruFocus
FibroGen Inc Reports Q1 2025 Earnings: Revenue Surpasses Estimat - GuruFocus
FibroGen: Q1 Earnings Snapshot - San Antonio Express-News
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
FIBROGEN INC SEC 10-Q Report - TradingView
Fibrogen Inc (FGEN) 財務データ
収益
当期純利益
現金流量
EPS
Fibrogen Inc (FGEN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
1.80%
0.18%
大文字化:
|
ボリューム (24 時間):